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Objectives: Since 2004, the government of Tanzania has been rolling out antiretroviral treatment programs all over
the country. However, the capacity of the health system to cope with the rapid scale-up of these programs is a
major concern, and problems may result in drug stock-outs that force changes in treatment regimens. This study
aims to explore stock-outs of antiretroviral drugs and further determine the coping strategies employed to prevent
changes in treatment regimens in HIV/AIDS care and treatment clinics in Kinondoni District, Dar es Salaam,
Tanzania.
Methods: A cross-sectional study was conducted in 20 HIV/AIDS care and treatment clinics. Interviews were
conducted with the person in charge and a member of the pharmacy staff from each clinic using a pre-tested
semi-structured interview guide. Verbal responses were transcribed, coded and analysed by thematic approach.
Quantitative data were analysed using Excel spreadsheet (Microsoft Excel®, Microsoft Corporation).
Results: The total number of clients enrolled in the visited clinics was 32,147, of whom 20,831 (64.8%) had already
been initiated onto antiretroviral therapies (ART). Stock-out of antiretroviral drugs was reported in 16 out of the 20
clinics, causing 210 patients to change their ART regimens, during the 12 months preceding the survey. Inefficient
supply systems, quantification problems and short expiry duration were cited as the main causes of stock-outs. The
coping strategies utilised to prevent changes in ART regimens were: shortening of the refill period, borrowing and
moving patients to other clinics.
Conclusion: Changes in ART regimens due to stock-outs of antiretroviral drugs occurred in a small but significant
number of patients. This increases the risk of the emergence of drug-resistant HIV strains. Healthcare workers use
various coping strategies to prevent changes in ART regimens but, unfortunately, some of these strategies are likely
to increase patient-borne costs, which may discourage them from attending their routine clinics, hence leading to
unplanned treatment interruptions.
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A total of 34 million people were living with HIV/AIDS
worldwide and 8 million were already on antiretroviral
therapies (ART) by the end of 2011 [1]. Increased access
to antiretroviral drugs has brought hope to millions of
people living with HIV/AIDS, especially in sub-Saharan* Correspondence: pax_amani@yahoo.com
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HIV/AIDS-related deaths in sub-Saharan Africa has de-
clined by 32% [1]. An intensified scaling-up of treatment
programs has caused a substantial reduction in HIV/
AIDS-related deaths as well as a significant reduction in
transmission rates [1,2]. The global target is to ensure
that 15 million people have been placed on treatment by
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[3], of whom 1.6 million were estimated to have been in-
fected with HIV by the end of 2012 [4]. The cumulative
number of people who had been enrolled in HIV/AIDS
care and treatment programs in the country was
1,135,390 and of these, 663,911 (58.4%) were already re-
ceiving ART by the end of December 2012 [4]. Since the
late 2000s, the Government of Tanzania has been scaling
up the enrolment of patients onto HIV/AIDS care and
treatment programs through provider-initiated and
home-based testing and counselling programs in order
to reach more patients [5,6].
By the end of December 2012, about 1,176 approved
health facilities, both public and private, were providing
HIV/AIDS care and treatment services in Tanzania [4].
The Medical Store Department (MSD) is a public agency
which procures, stores and distributes medicines in the
public health sector. In 2005, Tanzania adopted a pull
system called the Integrated Logistic System (ILS),
through which health facilities order their medical sup-
plies from MSD using a single set of procedures. This
system also handles supplies for vertical programs such
as vaccines and antiretroviral drugs [7,8]. With the ILS
system, hospitals order medicines quarterly directly from
MSD while dispensaries and health centres order
through the District Medical Officers’ (DMO) offices [7].
HIV/AIDS programs are largely funded by donors;
some prefer to procure antiretroviral drugs through the
MSD, while others use their own agents but rely on the
MSD for storage and distribution to the clinics based on
their program plans [9]. The MSD, through its extensive
distribution network consisting of nine zonal warehouses
located in different regions, delivers the ordered medi-
cines directly to the facilities or to the DMO’s office
[10]. Thus the performance of ART programs in Tanzania
largely depends on the smooth functioning of the MSD.
Unfortunately, it faces a number of challenges, some of
which are associated with the expansion of the ART pro-
grams [11,12].
HIV/AIDS treatment guidelines in Tanzania
In February 2009, the Ministry of Health and Social Wel-
fare (MoHSW) launched the third edition of its national
HIV/AIDS treatment guidelines, which recommended
ART to be initiated for all patients with CD4 cell counts
less than 200/mm3. The default first-line regimen was Zi-
dovudine + Lamivudine + Efavirenz or Nevirapine. Other
regimens include: Tenofovir + Emtricitabine + Efavirenz
or Nevirapine and Tenofovir + Lamivudine + Efavirenz or
Nevirapine [13]. In April 2012, the fourth edition of the
guidelines was launched [14], following the WHO’s rec-
ommendations of September 2009 which called for the
initiation of ART for all patients with CD4 cell counts
less than 350/mm3 [15]. This cut-off point has increasedthe number of patients who are eligible for ART, hence
adding more pressure to the already weak and fragile
pharmaceutical system.
Changes in ART regimens due to stock-outs
Changes in ART regimens due to stock-outs of anti-
retroviral drugs are common, particularly in low-income
countries [16,17]. The WHO’s progress report of 2010
reported that stock-outs of antiretroviral drugs were
documented in 36 out of the 94 reporting countries [18].
In 2011, Global Fund reported risks of antiretroviral
drug stock-outs in 20 African countries, and in one
country a number of these drugs were already out of
stock [19]. A study by Somi et al. in 2009 in Tanzania re-
ported that 247 patients changed their ART regimens
between 2004 and 2007 due to stock-outs of antiretro-
viral drugs [17]. The National AIDS Control Programme
also reported that about 10% of the 7,622 ART regimen
changes recorded in 2009 were due to stock-outs [20].
This study aims to explore stock-outs of antiretroviral
drugs and further determine the coping strategies
employed to prevent ART regimen changes in HIV/
AIDS clinics located in Kinondoni district, in Tanzania.
Methods
Study type
This was a cross-sectional study conducted in 20 HIV/
AIDS care and treatment clinics located in Kinondoni
district in Dar es Salaam region. There were 12 public
facilities in the sample, seven were private and one
belonged to a parastatal institution. Half were hospitals
and the rest were primary healthcare facilities. Five
clinics were being used as refill centres for patients who
had been initiated onto ART elsewhere.
Study setting
The study was conducted in Kinondoni District, in Dar
es Salaam, Tanzania. Dar es Salaam consists of three dis-
tricts and is the main business city in Tanzania; it also
hosts the headquarters of the Medical Store Department.
Kinondoni is a typical urban area (531 km2) with 27
wards which are further subdivided into 127 hamlets.
The district hosts about 1.7 million of the 4.5 million
people living in Dar es Salaam [3]. Generally, Dar es Sa-
laam has a poor public transport system consisting of
small buses locally called daladala with a capacity ran-
ging from 16–35 passengers. During peak hours, usually
in the morning and evening, these buses are over-
crowded and roads are usually congested.
The prevalence of HIV in Dar es Salaam among people
aged 15–49 years in 2011–2012 was 6.9% (9.2% in fe-
males and 5.3% in males). As of 2008, the municipality
hosted 18 approved HIV/AIDS care and treatment
clinics [20] and the certification of more facilities was an
Table 1 Number of clients enrolled in HIV/AIDS care and
treatment programs
Number enrolled Initiated onto treatment
Males 9,813 (30.5%) 7,422 (75.6%)
Females 22,334 (69.5%) 13,409 (60%)
Adults (15 years
and above)
30,404 (94.6%) 19,585 (64.4%)
Children (1–14 years) 1,743 (5.4%) 1,246 (71.5%)
Total 32,147 20,831 (64.8%)
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ducted there were about 20 approved clinics in Kinon-
doni. By December 2010, an estimated 123,345 people
living with HIV/AIDS in Dar es Salaam were enrolled in
65 care and treatment clinics and among them 72,513
(58.8%) had already been initiated onto ART [20].
Data collection and data collection tools
Data was collected from April to May 2011, so this data
set is almost three years old; hence the situation may
not be the same if a similar study was to be conducted
today. Data was mainly collected through in-depth inter-
views using a pre-tested semi-structured interview guide.
Interviews were conducted in the study clinics and re-
corded by a digital audio recording device.
Interview guide
The interview guide was composed of two sections; sec-
tion one for the in charge of the clinic and section two
for pharmacy staff (see Additional file 1).
Study participants
We selected two study participants from each clinic; the
person in charge of the clinic and one member of the
pharmacy staff. In the hospitals, the heads were mainly
medical doctors and the pharmacies were staffed by
pharmacists and pharmaceutical technicians. In the dis-
pensaries and health centres, heads were mostly Assist-
ant Medical Officers and frequently nurses were the
ones dispensing antiretroviral drugs.
Collection of quantitative data
Each clinic has a number of tools to record patient in-
formation for program monitoring. A pre-treatment
register records clients who are visiting the clinics for
the first time, whether they are eligible for treatment or
not, and the treatment register records clients who have
been initiated onto treatment. They also have monthly
and quarterly reporting tools which provide information
on the cumulative number of patients in care and under-
going treatment.
During our pre-visit, facility managers were given a
check-list of questions asking about the number of cli-
ents enrolled at their clinics and those who had already
been initiated onto ART. In addition, they were asked to
estimate the number of patients who had had their ART
regimens changed as a consequence of stock-outs during
the 12 months immediately preceding our survey.
Data analysis
A thematic content analysis approach was employed to
analyse the qualitative data [21] and the analysis was done
manually. Verbal responses from the interviewees were
transcribed shortly after each interview. The transcriptswere read and re-read several times in order to become
familiarised with their content. Transcripts were then
coded and similar or related codes were categorised
under the same thematic area. Quantitative data were
entered into Excel spreadsheets (Microsoft Excel®, Micro-
soft Corporation) and the outcome variables were re-
ported as absolute numbers and percentages.Data validity and ethical issues
To ensure data validity, the importance of the study was
emphasised to the informants and they were assured of
confidentiality. Phone numbers of the informants were
taken so that they could be contacted for clarification or
repeat interviews. Ethical clearance was granted by the
Ethics Review Committee of the Muhimbili University of
Health and Allied Sciences. Permission to collect data in
the clinics was sought from the facility managers, and all
the informants provided consent to participate in the
study.Definition of variables
Shortage is defined as a fall in the stock level of anti-
retroviral drugs below the level needed to maintain pa-
tients on their monthly refill period. Stock-out is defined
as the complete absence of one or more of the antiretro-
viral drugs that constitute the ART regimens of the
HIV/AIDS patients within the period of 12 months im-
mediately preceding the survey.Results
Table 1 gives summary information about the clients en-
rolled in the clinics. It shows that 32,147 clients were
enrolled in the visited clinics, of which 20,831 (64.8%)
had already been initiated onto ART. Children aged be-
tween 1–14 years accounted for 5.4% of those enrolled
and among them, 71.5% had already been initiated onto
ART. More females, 22,334 (69.5%), than males, 9,813
(30.5%), were enrolled in the clinics. The female-to-male
ratio of those who had already been initiated onto ART
was about 2:1.
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Stock-outs of antiretroviral drugs were reported in 16
out of the 20 clinics. Of these 16 clinics, 10 reported
ART regimen change affecting 210 patients, in five
clinics there were no records of those who had changed
ART regimens and in one clinic there was no change in
ART regimens at all. Regarding the stock-outs, one par-
ticipant said the following:
Yes at times antiretroviral drugs run out of stock; for
example Efavirenz was out of stock at some point this
year and this was a national problem. Therefore those
patients who were coming to refill their prescriptions
with Efavirenz were given Nevirapine. Some were not
happy with this but we had no alternative to keep
them on treatments. (Participant from Facility 12)
The majority of participants mentioned various com-
ponents of the pharmaceutical supply management
system, such as quantification problems, inefficient dis-
tribution and expiration due to short shelf-lives as the
main reasons for the stock-outs of antiretroviral drugs in
their clinics. They said that many problems originate
from the supplier side, as elaborated by one participant,
who said the following:
Most of the time I would say the problems begin at the
Medical Store Department, because at times you place
the order and you are told that certain medicines are
out of stock. On other occasions they deliver
antiretroviral drugs with very short shelf-lives which
expire on the shelves shortly after they have arrived at
the facility. (Participant from Facility 11)
Regarding quantification, the majority of participants
said that it is not easy to accurately predict the con-
sumption rate of the medicines as the number of pa-
tients initiated onto ART is constantly changing. One
participant said:
When you want to place the order you need to know
exactly how many patients will be initiated on
antiretroviral treatments in that period, but if the
number of patients keeps changing from time to time it
becomes difficult to estimate. And if you order too
many doses they may expire since some have a short
shelf-life. (Participant from facility 9)
Coping strategies used to prevent changes in
treatment regimens
Healthcare workers in the clinics which experienced short-
ages and stock-outs of antiretroviral drugs said that they
use various strategies, described below, in attempts to pre-
vent the need for patients to change their ART regimens.Shortening the refill period
The majority of participants said that when they experi-
ence shortages of antiretroviral drugs, the first strategy
they use is to shorten the refill period. Thus they give
patients a smaller number of pills, usually sufficient to
keep them on treatment for two weeks rather than a
month. Then, after they have replenished their stock,
they give them out on a monthly basis. One participant
said the following:
The major approach we use here when our stock falls
is to shorten the refill period; instead of giving them a
monthly dose we give them enough for a shorter time
so that other patients can also get the medicines. For
example, now the refill period for Efavirenz is two
weeks instead of one month. If we do it like this every
patient will get some pills for some time and if the
drugs arrive on time they will receive the usual
monthly dose when they come again to refill their
prescriptions. (Participant from Facility 7)
Borrowing from other facilities
We learned through the interviews that some clinics
place larger orders for antiretroviral drugs than they can
use in order to cope with irregular increases in patient
numbers or stock-outs at the central level. Therefore, it
was not surprising that participants, mostly from clinics
with a relatively small number of patients, said that they
borrow from other clinics which may have a larger stock
of the required antiretroviral drugs. One participant said:
We usually borrow from other nearby centres when we
are faced with shortages. It is a normal thing to
borrow; once we receive our supplies we return the
amount we borrowed. We work by helping each other.
(Participant from Facility 20)
Moving patients to other facilities
This strategy, although not very common, was also men-
tioned, especially for those clinics that were established
as refill centres in order to minimise congestion at the
higher-level facilities. One participant said:
This clinic is just a refill centre, patients just come here
to refill their prescriptions but all the clinical issues are
conducted at the hospital. So at times when they come
to refill and we do not have the drugs we tell them to
go to the hospital where they usually go for their
routine clinical check-up. (Participant from Facility 2)
What happens when the missing drugs become
available again?
All the participants said that usually they inform patients
about the reasons for changing their ART regimens and
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change can be permanent or temporary depending on
the patient’s experience with the new therapy or the
availability of the drugs. One participant said:
The new drugs can cause them side-effects they had
never experienced before, so when they come to refill,
they complain and ask if the drugs they were using
previously have arrived. In this kind of a situation we
return them to their previous regimens as soon as we
can. (Participant from Facility 12)
They said, however, that some patients feel more com-
fortable with their new regimens; hence switching them
back becomes impossible.Discussion
Shortages of antiretroviral drugs leading to changes in
ART regimens were common in the surveyed HIV/AIDS
care and treatment clinics. The study also reveals that
different coping strategies were used to avoid changes in
ART regimens, which is important to reduce the risk of
the emergence of drug-resistant HIV strains [22]. Drug
resistance increases the risk of rapid disease progression
and is of major public health concern [23]. Also, resist-
ance to the first-line antiretroviral drugs imposes large
opportunity costs on the treatment programs since
second-line antiretroviral drugs are more expensive [24].
Shortening of the refill period was a common strategy
utilised to cope with the shortages of antiretroviral drugs.
This is important to ensure that patients are maintained
on their ART regimens; however, this strategy is associ-
ated with increased direct and indirect costs borne by pa-
tients and their families in accessing treatment [25]. Both
direct and indirect costs in accessing care are associated
with poor adherence to treatments [26-28] and treatment
interruptions [29]. Treatment interruptions are associ-
ated with high rates of drug resistance [30], rapid disease
progression and greater numbers of deaths [16,31].
An inefficient supply system and forecasting challenges
were cited as the main factors causing shortages and
stock-outs of antiretroviral drugs in the clinics. These
findings correlate with a Global Fund report which sin-
gled out weak forecasting, accelerated patient enrollment
and lengthy procurement processes as the main factors
behind antiretroviral drug stock-outs in African countries
[19]. Lack of adequate skills among healthcare workers to
use drugs efficiently, to quantify needs and to manage
stocks of antiretroviral drugs have also been reported by
several studies in Tanzania [32,33]. It has been argued
that the international targets that were set for ART pro-
grams greatly over-estimated the capacity of the health-
care systems in sub-Saharan African countries [34].Recently, the parliamentary committee found large
quantities of antiretroviral drugs that had expired at
MSD warehouses before being distributed to healthcare
facilities, highlighting some of the challenges reported in
the facilities. Reliable forecasting, coupled with appropri-
ate inventory management to ensure an uninterrupted
supply of antiretroviral drugs, are crucial in the perform-
ance of HIV/AIDS care and treatment programs [35].
Limitations of the study
This study provides a snap-shot evaluation of the per-
formance of the pharmaceutical system, which is under
increased pressure due to the scale-up of ART programs
in Tanzania. The study employed a purposive sampling
method, which limits the generalisation value of its find-
ings since the selected clinics may not give a true repre-
sentation of all the other HIV/AIDS care and treatment
clinics in the country.
The data presented in this paper was based on self-
reporting by the participating healthcare workers in the
selected clinics. We regret that the methodology used in
this paper was not sufficient to collect quantitative data
for higher-level analysis. Also, we did not interview pa-
tients or officials from the MSD, although we strongly
believe they possess important information related to
the findings of this study. Their views could have
strengthened the main conclusion of this study.
Conclusions
Changes in ART regimens due to stock-outs of antiretro-
viral drugs occurred in a small but significant number of
patients. This increases the risk of the emergence of
drug-resistant HIV strains. Healthcare workers use vari-
ous coping strategies to prevent changes in ART regi-
mens but, unfortunately, some of these strategies also
increase patient-borne costs. This may discourage them
from attending their routine clinics, causing unplanned
treatment interruptions. Strengthening the supply chain
management system is important, otherwise there is a
high risk of jeopardising the benefits of antiretroviral treat-
ment programs that have been witnessed in recent years.
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Additional file 1: The interview guide.
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